Research in Progress
Principal Investigator: Dr. Gregory Riggins
Research Institution: Johns Hopkins University
Disease: Medulloblastoma, Glioblastoma
Research Description: Medulloblastoma is the most common malignant brain tumor in children, and brain cancers are the second leading cause of pediatric cancer-related deaths. Dr. Riggins’s recent studies have shown the antiparasitic drug mebendazole to be effective in animal models of aggressive brain tumors, including advanced gliomas and medulloblastomas. Because mebendazole has a history of safe use in patients, it has a relatively short pathway to new clinical trials. Dr. Riggins and his team have improved the formulation and anticancer performance of oral mebendazole, and this Phase I trial will examine dosage levels in recurrent pediatric brain cancers resistant to therapy. They hope to demonstrate not only safety, but to eventually provide the evidence and rationale for future Phase II studies.
CWR funding role: Participating funder
Start date: Starting in 2016
Most recent report: Enrollment will begin soon, with an expected rate of 1-2 patients per month.
Anticipated next steps
→ Data published in a scientific journal and/or presented at a scientific conference
→ Data leveraged into larger philanthropic or government funding for this treatment